Clinical Trial

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas

Study acronym: ESPACE
Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-01-08; most recent amendment 2025-02-11.
Status change: Not Yet Recruiting → Recruiting 2020-11-12
Trial Details
NCT Number NCT04224064
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Conditions Liposarcoma, Atypical Lipomatous Tumor
Enrollment 158 participants
Start Date 2020-08-26
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-12